发布求助
文献互助 智能选刊 最新文献

International Journal of Hematologic Oncology最新文献

筛选
英文 中文
Nursing in patients with hematological malignancies. 恶性血液病患者的护理。
International Journal of Hematologic Oncology Pub Date : 2020-05-04 DOI: 10.2217/ijh-2020-0011
Hana Geres, Rouslan Kotchetkov
{"title":"Nursing in patients with hematological malignancies.","authors":"Hana Geres, Rouslan Kotchetkov","doi":"10.2217/ijh-2020-0011","DOIUrl":"https://doi.org/10.2217/ijh-2020-0011","url":null,"abstract":"Managing patients battling hematological malignancies is a multifaceted profession and may occur within several settings. High quality nursing care demands an adequate understanding of the wide spectrum of diseases and their impact on a patient’s ability to maintain homeostasis throughout the course of the disease. Impaired bone marrow function renders patients vulnerable to multiple complications. Nurses must be trained to care for patients with the appropriate additional precautions. They must be aware of common side effect profiles of varying treatment regimens and the signs and symptoms of hematological emergencies. Additionally, they facilitate important conversations between patients, their families and healthcare teams. This ensures that the psychosocial wellbeing of patients remains at the centre of all decisions and management plans.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"9 1","pages":"IJH24"},"PeriodicalIF":0.0,"publicationDate":"2020-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2020-0011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37912933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Safety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin's lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience. 奈吡坦/帕洛诺司琼和地塞米松治疗化疗不充分的经典霍奇金淋巴瘤患者的安全性和有效性:帕洛诺司琼和地塞米松预防化疗引起的恶心和呕吐:单中心现实经验
International Journal of Hematologic Oncology Pub Date : 2020-02-28 DOI: 10.2217/ijh-2020-0001
Vittorio R Zilioli, Cristina Muzi, Periana Minga, Paolo Codega, Lara Crucitti, Erika Meli, Anna Esposito, Claudia Panico, Chiara Rusconi, Roberto Cairoli
{"title":"Safety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin's lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience.","authors":"Vittorio R Zilioli,&nbsp;Cristina Muzi,&nbsp;Periana Minga,&nbsp;Paolo Codega,&nbsp;Lara Crucitti,&nbsp;Erika Meli,&nbsp;Anna Esposito,&nbsp;Claudia Panico,&nbsp;Chiara Rusconi,&nbsp;Roberto Cairoli","doi":"10.2217/ijh-2020-0001","DOIUrl":"https://doi.org/10.2217/ijh-2020-0001","url":null,"abstract":"<p><p>We analyzed safety of NEPA (netupitant/palonosetron) and dexamethasone (NEPA+DEX) for the management of chemotherapy-induced nausea and vomiting (CINV) in classical Hodgkin's lymphoma patients that experienced CINV with a prophylaxis with palonosetron (PALO + DEX). In a retrospective, monocentric, noncomparative study, we analyzed adverse events and CINV grading in patients who switched from PALO + DEX to NEPA + DEX. Among 32 patients treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) during the study period, 47% did not properly control CINV with PALO + DEX and were shifted to NEPA + DEX. Among these, 53.3% properly controlled CINV is for all the remaining chemotherapy cycles. We did not observe an increase of adverse events after switching to NEPA. In our study, NEPA did not show drug-drug interaction with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy agents and NEPA administration was well tolerated with mild and transient adverse events.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"9 1","pages":"IJH23"},"PeriodicalIF":0.0,"publicationDate":"2020-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2020-0001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37912932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response. R-CHOP联合b细胞受体/NF-κ b双靶向的I/II期一线研究，以分子评估治疗反应。
International Journal of Hematologic Oncology Pub Date : 2019-12-19 DOI: 10.2217/ijh-2019-0010
Sophy Denker, Aitomi Bittner, Il-Kang Na, Julia Kase, Mareike Frick, Ioannis Anagnostopoulos, Michael Hummel, Clemens A Schmitt
{"title":"A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response.","authors":"Sophy Denker,&nbsp;Aitomi Bittner,&nbsp;Il-Kang Na,&nbsp;Julia Kase,&nbsp;Mareike Frick,&nbsp;Ioannis Anagnostopoulos,&nbsp;Michael Hummel,&nbsp;Clemens A Schmitt","doi":"10.2217/ijh-2019-0010","DOIUrl":"https://doi.org/10.2217/ijh-2019-0010","url":null,"abstract":"<p><p>The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61-80 years of age with newly diagnosed CD20<sup>+</sup> diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ≥2). Patients receive standard chemotherapy (CHOP) plus immunotherapy (Rituximab), a biological agent (the proteasome inhibitor Bortezomib) and a signaling inhibitor (the Bruton's Tyrosine Kinase-targeting therapeutic Ibrutinib). Using an all-comers approach, but subjecting patients to another lymphoma biopsy acutely under first-cycle immune-chemo drug exposure, ImbruVeRCHOP seeks to identify an unbiased molecular responder signature that marks diffuse large B-cell lymphoma patients at risk and likely to benefit from this regimen as a double, proximal and distal B-cell receptor/NF-κB-co-targeting extension of the current R-CHOP standard of care. EudraCT-Number: 2015-003429-32; ClinicalTrials.gov identifier: NCT03129828.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"8 4","pages":"IJH20"},"PeriodicalIF":0.0,"publicationDate":"2019-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2019-0010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37512728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Outcome of donor and recipient sex match versus mismatch in stem cell transplant procedure. 干细胞移植过程中供体和受体性别匹配与不匹配的结果。
International Journal of Hematologic Oncology Pub Date : 2019-12-18 DOI: 10.2217/ijh-2019-0006
Natasha Ali, Hayat Ullah, Mohammad Usman Shaikh, Salman Naseem Adil
{"title":"Outcome of donor and recipient sex match versus mismatch in stem cell transplant procedure.","authors":"Natasha Ali,&nbsp;Hayat Ullah,&nbsp;Mohammad Usman Shaikh,&nbsp;Salman Naseem Adil","doi":"10.2217/ijh-2019-0006","DOIUrl":"https://doi.org/10.2217/ijh-2019-0006","url":null,"abstract":"<p><strong>Aim: </strong>We determined the frequency of graft-versus-host disease (GvHD) and overall survival (OS) in sex matched vs mismatched transplant.</p><p><strong>Methods: </strong>Medical records were analyzed of patients undergoing transplant from 2004 to 2016. Variables included age, sex of patient and donor, indication, conditioning regimen, stem cell source, frequency of GvHD and OS.</p><p><strong>Results: </strong>We performed n = 162 allogeneic stem cell transplants. The most common conditioning regimen was busulfan/cyclophosphamide (n = 64). There was no difference in the frequency of GvHD in both groups. The transplant related mortality was higher (8.7%) in sex-mismatched transplants. The OS in both groups was similar.</p><p><strong>Conclusion: </strong>Our study showed higher transplant-related mortality in sex-mismatched transplant. There was no difference in GvHD and OS in both groups.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"8 4","pages":"IJH21"},"PeriodicalIF":0.0,"publicationDate":"2019-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2019-0006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37512729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Rational targeted therapeutics for double-hit lymphoma. 双发淋巴瘤的合理靶向治疗。
International Journal of Hematologic Oncology Pub Date : 2019-08-21 DOI: 10.2217/ijh-2019-0009
Nancy G Azizian, Yuanhui Liu, Lan V Pham, Yulin Li
{"title":"Rational targeted therapeutics for double-hit lymphoma.","authors":"Nancy G Azizian,&nbsp;Yuanhui Liu,&nbsp;Lan V Pham,&nbsp;Yulin Li","doi":"10.2217/ijh-2019-0009","DOIUrl":"https://doi.org/10.2217/ijh-2019-0009","url":null,"abstract":"<p><p>\"Double-hit lymphomas with MYC and BCL2 translocations can be effectively treated by combined targeting of the driver oncogenes\".</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"8 3","pages":"IJH19"},"PeriodicalIF":0.0,"publicationDate":"2019-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2019-0009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37468825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Evaluation of multiplexed biomarkers in assessment of CSF infiltration in pediatric acute lymphoblastic leukemia. 儿童急性淋巴细胞白血病脑脊液浸润的多重生物标志物评价。
International Journal of Hematologic Oncology Pub Date : 2019-08-12 DOI: 10.2217/ijh-2019-0008
Neveen L Mikhael, Myriam Abo Seif H Gendi, Hoda Hassab, Elshaymaa A Megahed
{"title":"Evaluation of multiplexed biomarkers in assessment of CSF infiltration in pediatric acute lymphoblastic leukemia.","authors":"Neveen L Mikhael,&nbsp;Myriam Abo Seif H Gendi,&nbsp;Hoda Hassab,&nbsp;Elshaymaa A Megahed","doi":"10.2217/ijh-2019-0008","DOIUrl":"https://doi.org/10.2217/ijh-2019-0008","url":null,"abstract":"<p><p>Acute lymphoblastic leukemia (ALL) is a very common pediatric malignancy with high survival rates. The course of treatment is modified according to the occurrence of central nervous system (CNS) disease. <b>Aim:</b> To relate serum and cerebrospinal fluid levels of five biomarkers (matrix metalloprotienase 9, CCL-2, sVCAM-1, IFN-γ and inducible protein 10) at diagnosis to the development of CNS infiltration. <b>Methods:</b> The present study was carried on 64 children with ALL and 20 controls. Multiplexed cytokines were measured by Luminex technology (Matrix metalloprotienase 9, CCL-2, sVCAM-1, IFN-γ and inducible protein 10). <b>Results:</b> Significantly higher sMMP-9 and lower sCCL2 were found in patients who developed CNS leukemia. <b>Conclusion:</b> Serum multiplexed parameters at diagnosis of childhood ALL may predict of development of CNS leukemia.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"8 3","pages":"IJH22"},"PeriodicalIF":0.0,"publicationDate":"2019-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2019-0008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37468828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Corrigendum. 勘误表。
International Journal of Hematologic Oncology Pub Date : 2019-08-01 DOI: 10.2217/ijh.15.13c1
{"title":"Corrigendum.","authors":"","doi":"10.2217/ijh.15.13c1","DOIUrl":"https://doi.org/10.2217/ijh.15.13c1","url":null,"abstract":"[This corrects the article DOI: 10.2217/ijh.15.13.].","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"8 2 1","pages":"IJH18"},"PeriodicalIF":0.0,"publicationDate":"2019-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh.15.13c1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48013050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pediatric cancer, posttraumatic stress and fear-related neural circuitry 儿童癌症、创伤后应激和恐惧相关神经回路
International Journal of Hematologic Oncology Pub Date : 2019-07-11 DOI: 10.2217/ijh-2019-0002
H. Marusak, F. Harper, J. Taub, C. Rabinak
{"title":"Pediatric cancer, posttraumatic stress and fear-related neural circuitry","authors":"H. Marusak, F. Harper, J. Taub, C. Rabinak","doi":"10.2217/ijh-2019-0002","DOIUrl":"https://doi.org/10.2217/ijh-2019-0002","url":null,"abstract":"This review examines the neurobiological effects of pediatric cancer-related posttraumatic stress symptoms (PTSS). We first consider studies on prevalence and predictors of childhood cancer-related PTSS and compare these studies to those in typically developing (i.e., noncancer) populations. Then, we briefly introduce the brain regions implicated in PTSS and review neuroimaging studies examining the neural correlates of PTSS in noncancer populations. Next, we present a framework and recommendations for future research. In particular, concurrent evaluation of PTSS and neuroimaging, as well as sociodemographic, medical, family factors, and other life events, are needed to uncover mechanisms leading to cancer-related PTSS. We review findings from neuroimaging studies on childhood cancer and one recent study on cancer-related PTSS as a starting point in this line of research.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2019-0002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47433097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 9
Developments in chemotherapy for the treatment of acute myeloid leukemia 急性髓性白血病的化疗进展
International Journal of Hematologic Oncology Pub Date : 2019-07-11 DOI: 10.2217/ijh-2019-0004
M. Drummond
{"title":"Developments in chemotherapy for the treatment of acute myeloid leukemia","authors":"M. Drummond","doi":"10.2217/ijh-2019-0004","DOIUrl":"https://doi.org/10.2217/ijh-2019-0004","url":null,"abstract":"Mark Drummond obtained his medical degree from the University of Glasgow (UK) and since then has trained as a hematologist in the West of Scotland and the Canterbury District Health Board (Christchurch, New Zealand) and back at Glasgow University, where he also gained a PhD in chronic myeloid leukemia. He is currently a consultant hematologist and honorary senior lecturer at the Beatson Cancer Centre (Glasgow, UK) as well as an investigator on multiple UK and international clinical trials. Here he talks to Commissioning Editor Jennifer Straiton, commenting on the recent announcement from the Scottish Medicines Consortium, regarding their acceptance of the use of the combination chemotherapy treatment Vyxeos® (daunorubicin and cytarabine) for the treatment of high-risk acute myeloid leukemia in adults. He then discusses the ongoing and future clinical trials in this disease area and then turns to more personalized treatments.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2019-0004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42901858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The importance of early intervention in the treatment of hepatic veno-occlusive disease 早期干预在肝静脉闭塞性疾病治疗中的重要性
International Journal of Hematologic Oncology Pub Date : 2019-07-11 DOI: 10.2217/IJH-2019-0003
A. Pagliuca
{"title":"The importance of early intervention in the treatment of hepatic veno-occlusive disease","authors":"A. Pagliuca","doi":"10.2217/IJH-2019-0003","DOIUrl":"https://doi.org/10.2217/IJH-2019-0003","url":null,"abstract":"Antonio Pagliuca is Professor of hematopoietic stem cell transplantation at King’s College London (UK) and medical director at King’s College Hospital where, until last year, he had been the transplant director for the past 24 years. He also has roles within NHS England as national clinical lead for regenerative medicine and is a trustee on both the Anthony Nolan trust (London, UK) and Leukemia UK (London, UK). Here he speaks to Commissioning Editor Jennifer Straiton and discusses the interim results of the DEFIFrance study, recently presented at the European Society for Blood and Marrow Transplant (EBMT), which looked at the real-world use of the European Society for Blood and Marrow Transplant severity grading criteria. The study investigates the use of defibrotide as a treatment of patients with post-transplant hepatic veno-occlusive disease and demonstrates how it can benefit from early intervention.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJH-2019-0003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46078455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信